protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
Company profile
Ticker
TARA
Exchange
Website
CEO
Jesse Shefferman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Proteon Securities Corp. • Proteon International Holdings, Inc. • Proteon Bermuda Limited • Proteon Ireland Limited ...
TARA stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
5 Apr 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
13 Mar 24
EFFECT
Notice of effectiveness
15 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
7 Nov 23
S-3
Shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
Latest ownership filings
SC 13G
CITADEL ADVISORS LLC
22 Apr 24
SC 13G
CVI Investments, Inc.
9 Apr 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
4
Jesse Shefferman
23 Jan 24
4
Jathin Bandari
23 Jan 24
4
Jacqueline Zummo
23 Jan 24
4
Patrick Fabbio
23 Jan 24
4
Hannah Fry
23 Jan 24
4
Jesse Shefferman
12 Jan 24
4
Jacqueline Zummo
12 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.51 mm | 34.51 mm | 34.51 mm | 34.51 mm | 34.51 mm | 34.51 mm |
Cash burn (monthly) | 70.00 k | 1.14 mm | 3.57 mm | 6.01 mm | 2.19 mm | 2.82 mm |
Cash used (since last report) | 475.60 k | 7.77 mm | 24.23 mm | 40.81 mm | 14.86 mm | 19.18 mm |
Cash remaining | 34.04 mm | 26.74 mm | 10.28 mm | -6.30 mm | 19.65 mm | 15.33 mm |
Runway (months of cash) | 486.2 | 23.4 | 2.9 | -1.0 | 9.0 | 5.4 |
Institutional ownership, Q2 2023
46.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 11.82 bn |
Total shares | 5.26 mm |
Total puts | 200.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Opaleye Management | 2.69 mm | $6.44 bn |
Orbimed Advisors | 772.58 k | $1.85 bn |
Vanguard | 427.61 k | $1.02 bn |
Boxer Capital | 209.23 k | $500.00 k |
Baker Bros. Advisors | 199.67 k | $477.21 mm |
Ikarian Capital | 188.66 k | $450.91 mm |
Fund Management B.V. Privium | 119.73 k | $271.79 mm |
Privium Fund Management | 119.73 k | $271.79 mm |
Renaissance Technologies | 83.60 k | $200.00 k |
Geode Capital Management | 83.42 k | $199.37 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Jan 24 | Jacqueline Zummo | Common Stock | Payment of exercise | Dispose F | No | No | 1.91 | 3,049 | 5.82 k | 104,296 |
19 Jan 24 | Jacqueline Zummo | Common Stock | Grant | Acquire A | No | No | 0 | 23,000 | 0.00 | 107,345 |
19 Jan 24 | Jacqueline Zummo | Stock Option Common Stock | Grant | Acquire A | No | No | 1.91 | 137,000 | 261.67 k | 137,000 |
19 Jan 24 | Patrick Fabbio | Common Stock | Grant | Acquire A | No | No | 0 | 22,000 | 0.00 | 22,000 |
19 Jan 24 | Patrick Fabbio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.91 | 131,000 | 250.21 k | 131,000 |
19 Jan 24 | Hannah Fry | Common Stock | Payment of exercise | Dispose F | No | No | 1.91 | 904 | 1.73 k | 29,836 |
19 Jan 24 | Hannah Fry | Common Stock | Grant | Acquire A | No | No | 0 | 8,000 | 0.00 | 30,740 |
19 Jan 24 | Hannah Fry | Stock Option Common Stock | Grant | Acquire A | No | No | 1.91 | 46,000 | 87.86 k | 46,000 |
19 Jan 24 | Shefferman Jesse | Common Stock | Payment of exercise | Dispose F | No | No | 1.91 | 7,803 | 14.90 k | 944,064 |
19 Jan 24 | Shefferman Jesse | Common Stock | Grant | Acquire A | No | No | 0 | 59,000 | 0.00 | 951,867 |
News
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
22 Apr 24
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $30
22 Apr 24
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Maintains $23 Price Target
8 Apr 24
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
5 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
Press releases
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
5 Apr 24
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
5 Apr 24
Protara Therapeutics to Participate in Upcoming Investor Conferences
31 Jan 24